| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma (NCT05116800) | Brown University | 2022-03-01 |
| ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (NCT05116683) | Benjamin Izar | 2022-01-11 |
| Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients (NCT07432932) | Royal Marsden NHS Foundation Trust | 2021-11-19 |
| A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents (NCT05094804) | OncoResponse, Inc. | 2021-09-09 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas (NCT04906876) | Brown University | 2021-09-01 |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (NCT04377932) | Baylor College of Medicine | 2021-08-08 |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (NCT05103631) | Baylor College of Medicine | 2021-06-17 |
| APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors (NCT04785196) | Ascentage Pharma Group Inc. | 2021-05-26 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (NCT04031677) | European Organisation for Research and Treatment of Cancer - EORTC | 2021-01-20 |
| Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma (NCT03880123) | Matthew Ingham | 2020-11-01 |
| Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (NCT04557449) | Pfizer | 2020-09-23 |
| Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas (NCT04224064) | Institut du Cancer de Montpellier - Val d'Aurelle | 2020-08-26 |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery (NCT02923778) | National Cancer Institute (NCI) | 2019-12-31 |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (NCT03899805) | Dana-Farber Cancer Institute | 2019-06-04 |
| Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin (NCT03773510) | Italian Sarcoma Group | 2019-02-28 |
| Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (NCT03526679) | National Taiwan University Hospital | 2018-07-12 |
| Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery (NCT03361436) | OHSU Knight Cancer Institute | 2018-03-19 |
| The FGF/FGFR Signalling Pathway: (NCT03303885) | Centre Hospitalier Universitaire de Nice | 2017-10-01 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall (NCT03651375) | Maria Sklodowska-Curie National Research Institute of Oncology | 2017-02-11 |
| Patient Reported Outcome Measures (PROMs) With Trabectedin (NCT03959033) | University of Leeds | 2016-11-29 |
| Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas (NCT02978859) | Columbia University | 2016-11-01 |
| A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma (NCT02571829) | Hadassah Medical Organization | 2016-05-01 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma (NCT02584309) | Washington University School of Medicine | 2016-02-22 |
| Detection of Circulating Tumor Cells in Patients With Sarcomas (NCT02983539) | AC Camargo Cancer Center | 2015-10-01 |
| Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) (NCT02609984) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2015-04-29 |
| Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma (NCT02343172) | Novartis Pharmaceuticals | 2015-03-13 |
| Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery (NCT02249949) | Alliance for Clinical Trials in Oncology | 2015-02-11 |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (NCT02275286) | Grupo Espanol de Investigacion en Sarcomas | 2014-11-01 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (NCT02180867) | National Cancer Institute (NCI) | 2014-08-12 |
| SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes (NCT02048371) | Sarcoma Alliance for Research through Collaboration | 2014-07-01 |
| Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma (NCT02247544) | Italian Sarcoma Group | 2014-03-01 |
| Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma (NCT01506596) | Vector Oncology | 2012-03-01 |
| Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas (NCT01426633) | Heidelberg University | 2011-11-01 |
| PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma (NCT01209598) | Memorial Sloan Kettering Cancer Center | 2010-09-23 |
| Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma (NCT01841047) | Institut Bergonié | 2009-01-20 |
| Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma (NCT00400569) | H. Lee Moffitt Cancer Center and Research Institute | 2006-11-01 |
| Bevacizumab and Radiation Therapy for Sarcomas (NCT00356031) | Massachusetts General Hospital | 2006-07-01 |
| Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) (NCT00093080) | Merck Sharp & Dohme LLC | 2004-10-01 |
| An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation (NCT00132704) | Memorial Sloan Kettering Cancer Center | 2004-08-01 |
| A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer (NCT00060944) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2003-05-01 |